Cohance Lifesciences Limited (COHANCE) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹443.5 (+0.34% day change)
Key ratios
- P/E ratio
- 94.56
- P/B ratio
- 2.95
- ROE (%)
- 4.58
- ROCE (%)
- 4.71
- Debt/Equity
- 0.1
- Dividend yield (%)
- 0
- Market cap (₹ Cr)
- 16,968.18
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 7.27 · Beneish M-Score: -1.17
InvestSights quality score
55/100 — Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Revenue: guided 8,500Rs Cr, delivered 2,268.6Rs Cr (FY26) — missed guidance
- DMF/CEP filings: guided 10filings, delivered 13filings (FY26) — exceeded guidance
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from this concall is the stark divergence between Cohance's standalone operating health and the consolidated financial picture being distorted by NJ Bio. The standalone business generated revenue of ₹3,599 million at a 9.2% adjusted EBITDA margin, and Sapala delivered 2.5x revenue growth — both pointing to a functioning core. However, NJ Bio's…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.